FDA Poised to Make Impact on Underrepresented Populations in Clinical Studies
H1 Blog
JULY 30, 2024
The recent draft by the FDA introduces additional guidelines for Diversity Action Plans aimed at improving diversity in clinical research. Quality insights make a difference and H1 has the data needed to support compliance with FDA requirements and diverse clinical trials. Find out more by requesting a demo today.
Let's personalize your content